Fabogene

FaboGene is a South Korean biotechnology company dedicated to developing next-generation gene therapies for rare genetic disorders, with a primary focus on lysosomal storage diseases. The company utilizes adeno-associated virus (AAV) vectors to deliver functional genes to patients, aiming to provide long-term therapeutic benefits through a single administration. Its lead programs include FBG-101 for Fabry disease and FBG-102 for Pompe disease, both of which are currently in the pre-clinical development stage. FaboGene's approach emphasizes optimized vector design and enhanced expression profiles to improve safety and efficacy in treating metabolic deficiencies. The company was founded by industry veterans with significant experience in gene therapy development and is supported by prominent Korean venture capital firms.